Skip to main
NVO
NVO logo

Novo Nordisk (NVO) Stock Forecast & Price Target

Novo Nordisk (NVO) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 20%
Sell 20%
Strong Sell 0%

Bulls say

Novo Nordisk leads the global branded diabetes treatment market with approximately 20% market share, significantly benefiting from the expected 20% growth in North America, which is projected to boost revenue estimates to DKK 24.9 billion. The continued dominance of Wegovy and Ozempic, bolstered by their strong cultural and physician recognition, positions the company for robust sales growth moving forward. Additionally, the favorable outcomes from clinical trials, such as the SURMOUNT-5 trial, which demonstrated the superior efficacy of tirzepatide over semaglutide, further enhances Novo Nordisk's competitive edge in the diabetes and obesity treatment sectors.

Bears say

Novo Nordisk's stock faces a negative outlook primarily due to anticipated lower than expected revenue growth from its incretin products, Ozempic and Wegovy, which is projected to decline by 10%. Current revenue estimates for North America indicate a significant shortfall, with projections of DKK 12.8 billion for Wegovy in Q1 2025, notably below the consensus expectation of DKK 14.4 billion. This trend suggests potential challenges in meeting market expectations and could negatively impact future financial performance and investor sentiment.

Novo Nordisk (NVO) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novo Nordisk and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novo Nordisk (NVO) Forecast

Analysts have given Novo Nordisk (NVO) a Buy based on their latest research and market trends.

According to 5 analysts, Novo Nordisk (NVO) has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $80.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $80.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novo Nordisk (NVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.